Assessment of Platelet-derived GARP in Atherosclerotic Disease
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversité Catholique de Louvain
About this trial
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Older than 18 years
Able to give informed consent
Undergoing carotid or femoral endarterectomy
Disqualifiers
Younger than 18 years
Pregnant
Dialysis
Unable to give informed consent
Trial population
The study population will comprise patients undergoing femoral or carotid endarterectomy in our tertiary care center (Cliniques Universitaires Saint-Luc) for atherosclerotic disease who do not meet exclusion criteria.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Tissue sample and data collection
Other interventionTissue sample and data collection
Treatment groups
200 Participants
are divided into 1 treatment groupGroup A: Endarterectomy population1 intervention
Trial outcomes
Primary outcomes
1
GARP Expression in Platelets
The number of cells/area expressing the GARP protein will be assessed
Time frame
Throughout the entire study, approximately during 3 yearsSecondary outcomes
1
GARP Expression T Regulating Cells
The number of cells expressing GARP will be assessed as a number of cells / area
Time frame
Throughout the entire study, approximately during 3 years2
GARP Expression General
The type of cells expressing GARP will be assessed as a number of cells / area
Time frame
Throughout the entire study, approximately during 3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Université Catholique de Louvain
Lead sponsor
Fonds National de la Recherche Scientifique
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: